BioPharma Terug naar discussie overzicht

Leuk , kansrijk bedrijfje

1. [verwijderd] 29 januari 2006 20:40

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   DieGroeneGigant schreef:

   Wat maakt CNVX interessant ?
   
   print.chartnet.nl/Show.cgi?Img=73DC39...
   

   de vele "Major Holders" en de grote afstrafing die ze gehad hebben
   Maar heb ze puur voor de korte termijn ( 10-20 % )
2. [verwijderd] 31 januari 2006 14:35

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   eFoodSafety.com, Inc. Subsidiary, Knock-Out Technologies, Ltd.'s Citroxin O2 Ingestible Kills Avian Influenza in Independent Laboratory Testing; Bucks County Clinical Research Begins Testing on Influenza A and B
   
   SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jan. 31, 2006--Robert Bowker, President/CEO of Knock-Out Technologies, Ltd., a wholly owned subsidiary of eFoodSafety.com, Inc. (OTCBB: EFSF) announced today that Human Clinical Trials on Citroxin O2 ingestible have commenced.
   
   In independent laboratory testing, Citroxin O2 killed a strain of the Avian Influenza Virus. Bucks County Clinical Research, Inc., (BCCR) (http://bccrinc.com/), an FDA clinical facility begins testing on Influenza A and B Viruses to substantiate results. The tests are to be conducted under the direction of David J. Miller, D.O., FAAP, Executive Director of BCCR and Richard M. Goldfarb, M.D., FACS, Medical Director of Research & Development of BCCR, a Director of eFoodSafety.com, Inc., and President of MedElite, Inc., a wholly-owned subsidiary of eFoodSafety.com, Inc.
   
   After 100% successful eradication of a strain of Avian Influenza Virus in laboratory testing, Knock-Out Technologies will seek to impact in the clinical setting a reduction in severity and length of time influenza virus will affect the human population. Since Avian Influenza Virus cannot be studied in human subjects, we will set out to show the efficacy in the treatment of Influenza Viruses A and B, which mirror the Avian Influenza Virus.
   
   "This milestone of testing with Human Clinical Trials with our Citroxin O2 ingestible product will enable us to prove what our laboratory findings have demonstrated. This further allows us as a company, and for the benefit of our shareholders, a product that can be revolutionary in the challenge of the worrisome Avian Influenza Virus," stated Patricia-Ross Gruden, President/CEO of eFoodSafety.com, Inc.
   
   About eFoodSafety.com, Inc.
   
   eFoodSafety.com, Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and most recently became a distributor for Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes.
   
   
3. [verwijderd] 2 februari 2006 18:54

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Feb. 2, 2006--Robert Bowker, president/CEO of Knock-Out Technologies Ltd., a wholly owned subsidiary of eFoodSafety.com Inc. (OTCBB: EFSF - News), announced today that the Environmental Protection Agency (EPA) has issued Registration No. 82723-1 for the company's Big 6 Plus Germicidal product.
   
   
   Laboratory testing of the Big 6 Plus Germicidal has proved it eradicates E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus. Recently, there has been laboratory documentation that proved it also killed a strain of Avian Influenza, Candida Albicans, the most common fungal infection in immunosuppressed patients, as well as Stachybotrys Chartarum mold spores (Black Mold).
   
   "The functionality of this completely safe, broad-spectrum germicidal product allows us to pursue various health-related issues and markets, such as industrial areas, schools, veterinary facilities, hospitals, nursing homes, health facilities, and restaurants," stated Bowker.
   
   During the review of our application, the EPA assessed the hazards that may be posed by the Big 6 Plus Germicidal to human health and the environment, as well as examined the ingredients, the site on which it is to be used, the amount, the frequency and timing of its use, and storage and disposal practices. The EPA's evaluation concluded that the Big 6 Plus will not have adverse effects on humans, the environment and non-target species.
   
   "Through the extensive approval process by the EPA and its subsequent issuing of the registration number, we now have the recognized credibility to market the Big 6 Plus Germicidal product. We feel our company continues to document and seek the necessary credentials for all of our products to assure our customers and our shareholders that eFoodSafety.com will only produce and market proven technology," stated Patricia Ross-Gruden, president and CEO of eFoodSafety.com Inc.
   
   
4. [verwijderd] 2 februari 2006 19:11

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   maw , we lopen binnen yellow, of in ons hemd?
   
   mvg,ric
5. [verwijderd] 2 februari 2006 19:19

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Het gaat toch allemaal perfecto ? Dit nieuws is het beste wat het bedrijf kan overkomen. De hele wereld is bang van virussen en allerlei vreemde ziektes en nu mogen ze hun product op de markt brengen. Volgens mij gaat dit miljoenen opbrengen. De vraag is of je al winst moet gaan nemen of niet. Ik denk dat ik ´s lekker lang in dit aandeel ga blijven. Het is pas het begin ( hoop ik ) .....
6. [verwijderd] 5 februari 2006 18:59

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   maurice_ schreef:

   [quote=DieGroeneGigant]
   Wat maakt CNVX interessant ?
   
   print.chartnet.nl/Show.cgi?Img=73DC39...
   [/quote]
   
   de vele "Major Holders" en de grote afstrafing die ze gehad hebben
   Maar heb ze puur voor de korte termijn ( 10-20 % )
   

   en staat de ta er al iets beter voor GroeneGigant ik heb met een beetje geluk ( nieuws CancerVax and Micromet Announce Merger Agreement) de 20 % te pakken. probeer maandag de helft te verkopen voor 2+ en hou de rest nog even aan ook gezien de cash die ze hebben
   Total Cash (mrq): 60.26M
   Total Cash Per Share (mrq): 2.161
   
   Maurice
7. [verwijderd] 5 februari 2006 19:13

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Maurice,
   
   CNVX - CancerVax Corporation
   
   De 2.00 usd is weerstand. Sluiten we hierboven dan kunnen we richting 3 usd. Omzetten nemen ook toe en dat is positief. Zoniet dan blijven we voorlopig even in bandbreedte 1.31 - 2.00 usd. Verder positief is dat we boven de MA25 zijn beland hetgeen betekent dat de trend weer omhoog is/gaat.
   
   Niet verkeerd fonds lijkt mij.
   
   Lijkt mij verstandig om de helft nu op 2 usd te verkopen. Kans groot dat bij doorbraak de 2 usd nog een keer getest wordt. Tenzij er met een gap wordt doorgebroken.
   
   print.chartnet.nl/Show.cgi?Img=26E07B...
8. [verwijderd] 5 februari 2006 19:29

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Hallo Die Groene Gigant
   
   Bedankt voor je snelle en goede reactie, grafiekje ziet er beter uit als vorige week.
   
   Ik koop nog veel te veel op gevoel en het bio gebeuren blijft bij mij toch een beetje gokken ( ik kijk wel na bepaalde dingen binnen een bedrijf ) al gaat me dat redelijk af de laatste tijd. Vorige week ook lorus gekocht voor de lange termijn.
9. [verwijderd] 6 februari 2006 15:57

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Feb. 6, 2006--Robert Bowker, President/CEO of Knock-Out Technologies, Ltd., a wholly owned subsidiary of eFoodSafety.com, Inc. (OTCBB:EFSF - News), announced today that the company has created a safe, natural, ingestible product that can eradicate Lyme disease.
   
   
   The company anticipates commencing human clinical trials using the Lyme disease product within the next 30 days. Human clinical trials have already commenced on the first ingestible product, the Avian Influenza formula. The second ingestible product, the Candida Albicans formula, which kills the most common fungal infection in immunosuppressed patients, is scheduled to undergo human clinical trials shortly.
   
   Lyme disease is caused by the bacterium Borrelia burgdorferi and is transmitted to humans by the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system. Lyme disease is diagnosed based on symptoms, physical findings (e.g., rash), and the possibility of exposure to infected ticks; laboratory testing is helpful in the later stages of disease. The ticks that transmit Lyme disease can occasionally transmit other tick-borne diseases as well (Division of Vector-Borne Infectious Diseases; National Center for Infectious Diseases; Centers for Disease Control and Prevention; www.cdc.gov).
   
   "Based on the increasing incidence of Lyme disease and its prolonged debilitating symptoms, we feel our product will have a major impact on this serious health threat. We will pursue human clinical trials to prove our groundbreaking technology is effective in eradicating Lyme disease," stated Patricia Ross-Gruden, President and CEO of eFoodSafety.com, Inc.
   
   
10. [verwijderd] 6 februari 2006 21:50

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    DieGroeneGigant schreef:

    Maurice,
    
    CNVX - CancerVax Corporation
    
    De 2.00 usd is weerstand. Sluiten we hierboven dan kunnen we richting 3 usd. Omzetten nemen ook toe en dat is positief. Zoniet dan blijven we voorlopig even in bandbreedte 1.31 - 2.00 usd. Verder positief is dat we boven de MA25 zijn beland hetgeen betekent dat de trend weer omhoog is/gaat.
    
    Niet verkeerd fonds lijkt mij.
    
    Lijkt mij verstandig om de helft nu op 2 usd te verkopen. Kans groot dat bij doorbraak de 2 usd nog een keer getest wordt. Tenzij er met een gap wordt doorgebroken.
    
    print.chartnet.nl/Show.cgi?Img=26E07B...
    

    
    
    verkopen op de €2 is niet gelukt maar is 2.40 geworden hij loopt weer super vandaag
11. [verwijderd] 16 maart 2006 23:43

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    finance.yahoo.com/q/co?s=EFSF.OB
    
    Blijft met leuke berichten komen...
12. [verwijderd] 23 maart 2006 16:22

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    eFoodSafety.com Inc. Enters into MultiMillion-Dollar Worldwide Direct Marketing Campaign to Sell Anti-Acne Product
    Thursday March 23, 9:00 am ET
    Joint Venture Partner Projects First Full Year's U.S. Gross Revenues to Exceed $100 Million
    
    SCOTTSDALE, Ariz.--(BUSINESS WIRE)--March 23, 2006--eFoodSafety.com Inc. (OTCBB: EFSF - News) and CK41 Direct Inc. jointly announced today the signing of a joint venture agreement. CK41 Direct Inc. is a firm engaged in the marketing, production and distribution of infomercials. The board of directors of CK41 boasts several infomercial successes, such as "Ab Away Pro," "Body by Jake" fitness products and "Rapid White" tooth whitening system. Other successes include the "Ab Sculptor" with more than $100 million in sales and the "Ab Doer" with sales in excess of $350 million.
    
    ADVERTISEMENT
    [0]
    The agreement calls for CK41 to handle and fund all aspects of the production, distribution and marketing of the anti-acne product, whose leading competition in the marketplace had sales in excess of $300 million last year.
    
    eFoodSafety.com Inc. will soon announce the branded and trademarked name of the product, as well as its high-profile celebrity spokesperson. Within the next 60 days, CK41 will commence the scripting and production of the infomercial.
    
    "CK41 anticipates estimated revenue at more than $100 million in gross sales in the first full year of the infomercial's national roll-out in the U.S. market alone," stated Christine McDonald, president and CEO of CK41 Direct. McDonald further stated, "Worldwide appeal for the product could easily approach $200 million as the leading competitor's sales have already exceeded $300 million last year."
    
    "We are elated to report this significant event to our shareholders. We have aligned ourselves with a joint venture partner who is well-capitalized, knowledgeable, focused on the product's target market, and has a seasoned staff and board of directors who have been an integral part of some of the most successful direct response campaigns ever launched," stated Patricia Gruden, president and CEO of eFoodSafety.com.
    
    About eFoodSafety.com Inc.
    
    eFoodSafety.com Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Big 6 Plus -- EPA Reg. No. 82723-1, that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, and Avian Influenza and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and most recently became a distributor for Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes.
    
    Safe Harbor Forward-Looking Statements
    
    Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements invoke risk and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
    
    Contact:
    
    Redwood Consultants, LLC
    Jens Dalsgaard, 415-884-0348
13. [verwijderd] 23 maart 2006 23:30

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    kijk eens aan, beweging, 33 ct zowaar,alles is meegenomen. nog geen 1% van de portefeuille , maar toch leuk .
14. [verwijderd] 27 maart 2006 17:27

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    komt beweging +17%
15. [verwijderd] 27 maart 2006 17:36

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    eFoodSafety.com, Inc. Completes Bird Flu Formulation
    Monday March 27, 10:15 am ET
    EFSF Believes It Has Formulated the 'Total Solution' to the Potential Bird Flu Pandemic
    
    SCOTTSDALE, Ariz.--(BUSINESS WIRE)--March 27, 2006--Patricia Gruden, President/CEO of eFoodSafety.com, Inc. (OTCBB:EFSF - News), announced today that eFoodSafety.com, Inc. has completed its product formulations on what it calls the "Total Solution" to the potential Bird Flu pandemic. eFoodSafety's Citroxin formulation has definitively proven in independent laboratory testing to eliminate the H9N2 virus, which is the surrogate organism used in all laboratory testing for the Bird Flu, on both hard and porous surfaces.
    ADVERTISEMENT
    
    
    
    
    
    eFoodSafety's Citroxin formulation can be sprayed on bird cages and hen houses without it being harmful to animals or humans in surrounding areas if ingested.
    
    Humans who have contracted the H5N1 virus, commonly known as Bird Flu, can rely on eFoodSafety's Citroxin O2 formulation, an ingestible product that the company believes will prove to have dramatic effects on the Bird Flu virus. The Citroxin O2 formulation is currently undergoing human clinical trials on the Influenza Viruses A and B, however testimonials from humans who have taken the product with influenza-like symptoms indicate very promising results.
    
    The company further reports that interest in the Citroxin formulations from large multi-billion dollar pharmaceutical corporations has been very encouraging and anticipates pursuing all opportunities presented.
    
    "It is eFoodSafety's contention that these two products can prevent the spread and effectively treat the potential pandemic Bird Flu virus. We anticipate the product will soon be ready for mass production and distribution," stated Mrs. Gruden.
    
    
16. [verwijderd] 27 maart 2006 23:05

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    EFOODSAFETY.COM INC (OTC BB:EFSF.OB) Delayed quote data Edit
    Last Trade: 0.485
    Trade Time: 3:49PM ET
    Change: Up 0.17 (53.97%)
    Prev Close: 0.315
    Open: 0.315
    Bid: 0.485 x 5000
    Ask: 0.49 x 5000
    1y Target Est: N/A
    
    Day's Range: 0.315 - 0.50
    52wk Range: 0.16 - 0.46
    Volume: 17,709,738
    Avg Vol (3m): 462,787
    Market Cap: 58.37M
    P/E (ttm): N/A
    EPS (ttm): -0.053
    Div & Yield: N/A (N/A)
17. [verwijderd] 28 maart 2006 10:34

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Kun je bij Alex handelen zo ja wat is de code
18. Striker_ 28 maart 2006 11:29

    auteur info

    • Striker_

      Lid sinds: 09 mrt 2004

      Laatste bezoek: 05 feb 2025

    • Aanbevelingen

      Ontvangen: 45

      Gegeven: 15

    •    Aantal posts: 2.834

    ben je nu al een beetje laat denk je ook niet??
19. [verwijderd] 28 maart 2006 12:33

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Kees33 schreef:

    eFoodSafety.com Inc. Enters into MultiMillion-Dollar Worldwide Direct Marketing Campaign to Sell Anti-Acne Product
    Thursday March 23, 9:00 am ET
    Joint Venture Partner Projects First Full Year's U.S. Gross Revenues to Exceed $100 Million
    
    [/quote]
    
    Dat is al ongeveer een dollar per aandeel, en dan is het middel tegen het vogelgriepvirus nog niet eens meegerekend.
    
    [quote=Kees33]
    The company further reports that interest in the Citroxin formulations from large multi-billion dollar pharmaceutical corporations has been very encouraging and anticipates pursuing all opportunities presented.
    

    Er zou nog best wat in het vat kunnen zitten.
20. [verwijderd] 28 maart 2006 13:25

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Sorry hoor, stel gewoon een vraag, weleens gehoord van opslaan in je watchlist. Bedankt hoor. Waar is een forum eigenlijk voor.?